Vident Advisory LLC Invests $289,000 in Bausch + Lomb Corporation $BLCO

Key Points

• Vident Advisory LLC invested approximately $289,000 in Bausch + Lomb Corporation, acquiring 19,898 shares during the 1st quarter, as reported in their Form 13F filing.
• Multiple institutional investors increased their holdings in Bausch + Lomb, with National Bank of Canada boosting its stake by 101.7% in the same period.
• Analysts have mixed views on the stock, with target price adjustments ranging from $12.00 to $19.00 and a consensus rating of "Hold" despite three analysts rating it as a Buy.

Vident Advisory LLC purchased a new position in shares of Bausch + Lomb Corporation (NYSE:BLCO - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 19,898 shares of the company's stock, valued at approximately $289,000.

Several other institutional investors have also modified their holdings of BLCO. National Bank of Canada FI boosted its stake in shares of Bausch + Lomb by 101.7% during the 1st quarter. National Bank of Canada FI now owns 6,719 shares of the company's stock worth $97,000 after acquiring an additional 3,387 shares in the last quarter. Alpine Global Management LLC purchased a new stake in shares of Bausch + Lomb during the 4th quarter worth approximately $181,000. State of Wyoming boosted its stake in shares of Bausch + Lomb by 47.7% during the 1st quarter. State of Wyoming now owns 19,972 shares of the company's stock worth $290,000 after acquiring an additional 6,447 shares in the last quarter. Trexquant Investment LP boosted its stake in shares of Bausch + Lomb by 5.8% during the 1st quarter. Trexquant Investment LP now owns 20,255 shares of the company's stock worth $294,000 after acquiring an additional 1,108 shares in the last quarter. Finally, Tabor Asset Management LP purchased a new stake in Bausch + Lomb in the 1st quarter valued at approximately $338,000. Hedge funds and other institutional investors own 11.07% of the company's stock.

Analyst Upgrades and Downgrades

BLCO has been the topic of a number of recent research reports. Barclays reduced their target price on Bausch + Lomb from $19.00 to $16.00 and set an "equal weight" rating on the stock in a research note on Monday, June 9th. Morgan Stanley upped their target price on Bausch + Lomb from $12.00 to $13.00 and gave the company an "equal weight" rating in a research note on Friday, August 1st. Zacks Research raised Bausch + Lomb to a "hold" rating in a research note on Tuesday, August 12th. Wells Fargo & Company upped their target price on Bausch + Lomb from $12.00 to $15.00 and gave the company an "equal weight" rating in a research note on Thursday, July 31st. Finally, Evercore ISI upped their target price on Bausch + Lomb from $15.50 to $16.00 and gave the company an "outperform" rating in a research note on Tuesday, July 8th. Three equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $15.56.

Bausch + Lomb Trading Down 1.3%

Shares of BLCO opened at $15.33 on Wednesday. The stock has a fifty day moving average of $14.24 and a two-hundred day moving average of $13.44. The company has a debt-to-equity ratio of 0.76, a quick ratio of 0.98 and a current ratio of 1.55. The company has a market capitalization of $5.43 billion, a PE ratio of -19.65, a price-to-earnings-growth ratio of 1.58 and a beta of 0.63. Bausch + Lomb Corporation has a fifty-two week low of $10.45 and a fifty-two week high of $21.69.

Bausch + Lomb (NYSE:BLCO - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The company reported $0.07 EPS for the quarter, topping analysts' consensus estimates of $0.06 by $0.01. The business had revenue of $1.28 billion during the quarter, compared to the consensus estimate of $1.25 billion. Bausch + Lomb had a positive return on equity of 2.33% and a negative net margin of 5.58%.The business's revenue for the quarter was up 5.1% on a year-over-year basis. During the same period in the prior year, the firm posted $0.13 EPS. Bausch + Lomb has set its FY 2025 guidance at EPS. As a group, analysts forecast that Bausch + Lomb Corporation will post 0.74 EPS for the current year.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.